ReviewOncology letters2026
Advances in targeting vasculogenic mimicry in malignant tumors using monomeric compounds from Traditional Chinese Medicine (Review).
Review in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vasculogenic mimicry (VM), a pivotal mechanism underlying tumor resistance to anti-angiogenic therapies, presents key challenges in oncology treatment. Chinese herbal monomers exhibit notable therapeutic potential in cancer treatment, particularly regarding their capacity to inhibit tumor VM formation. However, to the best of our knowledge, no comprehensive literature review has systematically explored the specific molecular mechanisms through which Chinese herbal monomers exert their anti-VM effects in tumor cells, to date. Therefore, the present systematic review evaluates the therapeutic potential of 46 natural monomers derived from Traditional Chinese Medicine (TCM) across 16 cancer types, through a comprehensive analysis of 64 preclinical studies. TCM monomers inhibit VM formation by modulating key signaling pathways (PI3K/AKT, MAPK and Notch) and downregulating key molecular markers (vascular endothelial-cadherin, MMPs and hypoxia inducible factor-1α). The identified compounds exhibit multi-target regulatory capabilities through epithelial-mesenchymal transition suppression, matrix metalloproteinase inhibition and angiogenesis-related signaling pathway modulation. These findings elucidate the mechanistic basis for the anti-VM effects of TCM and propose a novel therapeutic avenue to potentially overcome resistance in malignant tumors, highlighting the translational value of phytochemical-based combination therapies in precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.